Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055172 · ClinicalTrials.gov registry record
Genetic Basis of Immunodeficiency
A clinical trial of Severe Combined Immunodeficiency, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT00055172 is a study of Severe Combined Immunodeficiency that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 100 participants, below the 378-participant average among 5 other Severe Combined Immunodeficiency trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00055172, a study of Severe Combined Immunodeficiency, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the role of hereditary factors in different forms of severe combined immunodeficiency (SCID). Patients with immunodeficiencies may be eligible for this study. Candidates include: * Patients with diminished numbers of T cells or NK cells or both, or * Patients with normal T cell and NK cell numbers but diminished T cell, B cell, or NK cell function. Relatives of patients will also be studied. Participants will have blood samples collected for genetic analysis in studies related to SCID at the National Institutes of Health and other institutions. ...
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2004-04-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055172
The ClinicalTrials.gov registry entry for NCT00055172 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 378-participant average among 5 other Severe Combined Immunodeficiency trials with a reported enrollment target (74% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Combined Immunodeficiency appearing as the primary indexed condition, and to 0 interventions.
NCT00055172 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00055172 about?
NCT00055172 is a clinical study titled "Genetic Basis of Immunodeficiency". This study will examine the role of hereditary factors in different forms of severe combined immunodeficiency (SCID). Patients with immunodeficiencies may be eligible for this study. Candidates include: * Patients with diminished numbers of T cells or NK cells or both, or * Patients with normal T ...
What is the current status of trial NCT00055172?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2004-04-05.
What conditions does trial NCT00055172 study?
This clinical trial studies the following conditions: Severe Combined Immunodeficiency.
Who is sponsoring clinical trial NCT00055172?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055172 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Combined Immunodeficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Gene Therapy for Artemis-Deficient SCID
RECRUITING · Phase 1
-
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
ACTIVE NOT RECRUITING · Phase 1
-
Immune Disorder HSCT Protocol
ACTIVE NOT RECRUITING · Phase 2
-
Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
COMPLETED
-
Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID
COMPLETED
-
IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.